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PKAAnnexin A1 (ANXA1) is the ﬁrst characterized member of the annexins superfamily. It binds the cellular mem-
brane phospholipids in Ca2+ regulated manner. Annexin A1 has been found in several tissues andmany physio-
logical roles as hormones secretion, vesiculation, inﬂammatory response, apoptosis and differentiation have been
shown. Its subcellular localization and binding withmany partner proteins are altered accordingly with its phys-
iological role. The Annexin A1 membrane localization is crucial for binding to receptors, suggesting a paracrine
and juxtacrine extracellular action. Annexin A1 is subjected to several post-translational modiﬁcations. In partic-
ular the protein is phosphorylated on several residues both on the N-terminal functional domain and on the
C-terminus core. Different kinases have been identiﬁed as responsible for the phosphorylation status of selective
residues. The speciﬁc change in the phosphorylation status on the different sites alters ANXA1 localization, bind-
ing properties and functions. This review shows the physiological relevance of the ANXA1 phosphorylation lead-
ing to the conclusion that numerous and different roles of Annexin A1 could be associated with different
phosphorylations to alter not only intracellular localization and bindings to its partners but also the extracellular
receptor interactions.
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. Open access under CC BY-NC-ND licen1. Introduction
About 30 years ago, a 37 KDa protein was identiﬁed as a steroid-
induced inhibitor of phospholipase activity with potential anti-
inﬂammatory action. The protein was named lipocortin-1, lipomodulin,
macrocortin or renocortin. Currently it is mostly known as Annexin A1
(ANXA1).
It is phosphorylated in vivo by protein tyrosine and serine–
threonine kinases. During the years, many physiological functionsse.
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scribed. It was found that ANXA1 inhibits the phospholipase and it has
been proposed that this activity could be regulated by its phosphoryla-
tion. In 1986 Pepinsky & Sinclair described the phosphorylation of
Annexin A1 near its amino terminus by the protein tyrosine kinase ac-
tivity of the epidermal growth factor receptor (EGF-R) [1]. This study
has been updated and ampliﬁed by using recombinant Annexin A1 as
a substrate for several putative protein kinases. The authors identiﬁed
several phosphorylated residues by a combination of peptide mapping
and sequence analysis and showed that recombinant pp60c-src phos-
phorylates Annexin A1 near its amino terminus, at tyrosine 21
(Tyr21). Also polyoma virus middle T/pp60c-src complex, recombinant
pp50v-abl, and the EGF receptor/kinase phosphorylated the same tyro-
sine residue. It was also shown that serine 27 residue of ANXA1 is the
primary site phosphorylated by protein kinase C (PKC). In the same
study, the threonine 41 residue has been identiﬁed as a PKC substrate
as well. The adenosine cyclic 3′,5′-phosphate dependent protein kinase
A (PKA) phosphorylates ANXA1 in its carboxyl-terminal core at the
threonine 216 residue (Thr216) [2]. In 1988 Schlaepfer & Haigler
showed that PKC phosphorylated N-terminal peptides cleaved from
32P-labeled AnnexinA1 contain phosphorylated threonine-24, serine-
27, and serine-28 [3]. These studies raised the attention focus on the
ANXA1 phosphorylation status and its possible role in regulation of
the Annexin A1 functions (Fig. 1).
2. Initial studies of the phosphorylated Annexin A1
physiological roles
The annexins are a family of calcium-dependent, phospholipid-
binding proteins [4]. Annexin A1, as the other annexins, is activated in
its Ca2+-bound conformation to bind the membrane phospholipids
due to the exposure of its functional N-terminal domain. In contrast,
the Ca2+-free ANXA1 N-terminus is sterically hindered and not accessi-
ble [5]. Most of the ANXA1 functions are related to its ability to interact
with cellular membranes. This interaction is reversible and regulated
especially by post-translational modiﬁcations like phosphorylation.
Tyrosine phosphorylation decreases the ANXA1 Ca2+ requirement
for binding phosphatidylserine vesicles [6]. In 1992 Patte et al. pub-
lished that treatment of synchronized HUVE endothelial cells with
basic Fibroblast Growth Factor (bFGF) leads to tyrosine phosphorylation
of Annexin A1. According to the published results, the effect of bFGF on
ANXA1 phosphorylation occurs only during S phase of the cell cycle,
suggesting a role of the FGF-receptor/kinase complex [7].
Wang et al. showed that phosphorylation of the N-terminal domain
of ANXA1 by PKC induces chromafﬁn granules aggregation, responsible
for the secretion of hormones. Their study started with the evidence
that phosphorylation of serines of ANXA1 is induced by bovine chro-
mafﬁn secretion [8]. According to their results, the phosphorylation by
PKC of an unspeciﬁed residue leads to a strong inhibition of ANXA1Fig. 1. Schematic representation of the target residues and principal kinases involved in ANXA1
Chak1 — TRPM7 Channel Kinase 1; EGFR — Epidermal Growth Factor Receptor; PKC— Proteinaggregative ability. The mechanism of action is probably related to the
fourfold increase of Ca2+ requirement. The inhibitory effect was re-
versed by the phosphatase 2A mediated dephosphorylation of the
Annexin A1. On the other hand, the ANXA1 phosphorylation by PKC
was not able to interfere with the direct binding of ANXA1 to granules
or phosphatidylserine and phosphatidylcholine vesicles, leaving unex-
plained the inhibitory effect on ANXA1. For this reason, the authors
suggested, in an articulated discussion, an “unusualmechanism” of inhi-
bition involving a sort of not yet established competition mechanism
between the phosphorylated and unphosphorylated ANXA1 forms.
Moreover the authors proposed a role of ANXA1 in regulation of
hormones exocytosis via the ability to alter granules aggregation. [9]
However, the process must be further characterized to drive a ﬁnal
conclusion.
At the same time it was shown that low concentrations (5 μM) of
glycyrrhizin and a glycyrrhetinic acid derivative induced a protein
kinase A (PKA) mediated ANXA1 phosphorylation. Curiously, higher
concentrations of these compounds reverted completely the effect. As
the natural compound examined showed anti-inﬂammatory activity,
the conclusion and the speculation were that ANXA1 phosphorylation
may have a role in the anti-inﬂammatory effects of the studied drugs
[10].
Sawyer and Cohen showed that the ANXA1 phosphorylation is linked
with EGF-R internalization suggesting that the endosomal EGF-R kinase
may be involved in the phosphorylation of Annexin A1 [11]. Based on
their results, it was shown by Futter et al. that ANXA1 is a substrate of
EGF-R kinase in multivesicular bodies (MVBs, important for stimulated
EGF-R internalization and sorting). Interestingly, phosphorylating a
calcium-independent Annexin A1 converted it to a calcium-dependent
form. TheANXA1 phosphorylation has been suggested being responsible
for theMVBs inward vesiculation induced by EGF-R activation. The phos-
phorylatedANXA1 residue in this study is not shown.Other experiments
were performed using both in vitro and cell culture approaches [12].
Summarizing the results and recent literature covering this topic, it can
be concluded that ANXA1 is phosphorylated by EGF-R after internaliza-
tion via the multivesicular bodies. This phosphorylation is not calcium-
dependent but the phosphorylated Annexin A1 binds the phospholipids
in a calcium-dependent manner.
Protein Kinase C (PKC) catalyzed phosphorylation of Annexin A1
and 2 in cultured rat mesangial cells in vitro required presence of
Ca2+ and phospholipids. However, mere phospholipids were not sufﬁ-
cient to support the phosphorylation. In the experiments performed
in vivo on 32P-labeled mesangial cells, the ANXA 1 phosphorylation
was increased by the addition of PKC activators as angiotensin II
and phorbol myristate acetate (PMA). Moreover, a phosphoamino acid
analysis, either by using two-dimensional chromatography or speciﬁc
antiphosphotyrosine antibody, revealed that phosphorylation occurs
only on serine residues [13]. These results were updated and partially
conﬁrmed by a study performed on rat renal glomeruli and ratphosphorylation. S, Y, H and T are respectively Serine, Tyrosine, Histidine and Threonine.
Kinase C; PKA — Protein Kinase A.
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tensin II, arginine-vasopressin and endothelin I stimulated Annexin A1
phosphorylation after 10min from the treatment.Western blot analysis
with an anti-phosphotyrosine antibody conﬁrmed phosphorylation of
tyrosine residues. This data suggested a possible role of Annexin A1 in
mitogenic effect of angiotensin II, arginine-vasopressin, and endothelin
[14].
Ohnishi et al. showed that the phosphorylation of Annexin A1 was
markedly enhanced and it was associated with insulin secretion in rat
pancreatic islets stimulated by a high concentration of glucose
(20mM). In this case, the phosphorylation occurred mainly on serine
residues, as conﬁrmed by using H-7, a potent PKC inhibitor [15]. In
vitro, the phosphorylation of Annexin A1 by PKC was inhibited by
Annexin V, which is not a PKC substrate [16]. Interestingly, the ANXA1
serine phosphorylation was responsible for a dramatic decrease of
phospholipid vesicle aggregation. However, the ANXA1 phosphoryla-
tion did not alter its binding to the phospholipid vesicles [17]. It con-
ﬁrmed the idea that the phosphorylation of ANXA1 by PKC leads to
inhibition of membrane fusion activity induced by ANXA1. On the
other hand, another author in the same year, proposed the phosphory-
lation as the main activator of ANXA1 immunosuppressive activities
[18]. However, no speciﬁc phosphorylation sites were described. It
means that the phosphorylation of the protein does not necessarily
cause its inactivation.
Even though the relevance of ANXA1 phosphorylation by PKC is
widely accepted, it is important to remark that Farkas et al. published
that in permeabilized granulocytes at supra-physiological Ca2+ concen-
trations, PKC bound to the cytoplasmic surface of the plasmamembrane
and was not actually accessible for the complex Ca2+-ANXA1 [19].
3. Phosphorylation of the serine residue
In order to explain the role of the serine 27 phosphorylation, Porte
et al. generated two ANXA1 mutants; S27E and S27A mimicking and
preventing phosphorylation, respectively. Wild-type Annexin A1 and
the S27A mutant protein showed the same calcium dependence for
phospholipid vesicles aggregation. Adversely, the S27E mutant protein
exhibited higher calcium requirement and a lower aggregation activity,
conﬁrming the phosphorylation inhibitory theory. By contrast, the lipo-
some binding and self-association required identical calcium concentra-
tions for the wild-type and bothmutant proteins. This suggests that the
phosphorylation of serine 27 residue could inhibit only one of these
ANXA1 functions. Moreover, the authors have shown that the Ser27
phosphorylation induces a conformational change, which is probably
related to the described membrane aggregation property [20].
4. Phosphorylation of the tyrosine residue
Huang et al. published the ﬁrst results about in vitro experiments in-
volving the EGF kinase activity in the phosphorylation of a 35kDa PLA2
inhibitor protein, recognized as Annexin A1 [21].
Years later Salles et al. showed that growth factors and cytokines, in-
cluding epidermal growth factor, insulin, pp60v-scr, and angiotensin II,
are able to induce rapid tyrosine phosphorylation of Annexin A1 in an
osteoblast-like rat osteosarcoma cell-line. [22]. On the other hand, the
relevance of ANXA1 phosphorylation was still not fully clear, even
though a role of phosphorylated Annexin A1 in signal transduction was
suggested. In fact, tyrosine residue of ANXA1was efﬁciently phosphory-
lated within 10min after exposition to hepatocyte growth factor (HGF)
and it translocated to the membrane fraction of A549 lung carcinoma
cells. As antisense ANXA1 oligonucleotides reverted the HGF induced
cell proliferation, the authors suggested that the phosphorylation of
Annexin A1 may function as a “signal ampliﬁer” in processes where
the HGF receptor tyrosine kinase is activated. The proposed mechanism
of action is induction of the release of intercellularmessengers (as PGE2)with pluripotent roles in cell proliferation, chemotaxis, and vascular re-
modeling [23].
Tyrosine phosphorylated Annexin A1 promoted a dose-dependent
inhibition of Insulin Receptor (IR) auto-phosphorylation. This effect re-
quired phosphorylation of the ANXA1 N-terminal domain at Tyr21 res-
idue and was speciﬁc for insulin-stimulated tyrosine kinase activity.
These data underscore a speciﬁc interaction of IR with Annexin A1 [24].
Solito et al. correlated the expression of Annexin A1with phospholi-
pase A2 activity in U937 cells stimulated by PMA and LPS. They per-
formed both a sense and antisense ANXA1 plasmid transfection and
proposed that the endogenous non-phosphorylated form of Annexin
A1 may act intracellularly to block the cytosolic PLA2 activity. The au-
thors detected that only 10% of Annexin A1 is phosphorylated on tyro-
sine, suggesting that the phosphorylation is not required for this
function [25]. de Coupade et al. have shown that ANXA1 expression
and phosphorylation could be implicated in liver regeneration and tu-
morigenesis, either through modulation of cPLA (2) activity or EGF-R
function. Both the expression and the phosphorylation of Annexin A1
were increased upon EGF-R activation and consequent cancer growth
[26]. Interestingly, a study conducted by Croxtall et al., using a peptide
library, showed that the EQEYV domain is essential but not sufﬁcient
for some of ANXA1 activities. The peptides containing the EQEYV do-
main affected PLA2 activity, arachidonic acid release and A549 human
adenoma cell growth. The described domain is localized at the N-
terminal region of Annexin A1 and contains only the phosphorylatable
Tyr21 [27].
5. Phosphorylation of the histidine residue
With increasing interest in ANXA1 phosphorylation activity, other
groups joined the topic and some of them suggested interesting but
not anymore explored inputs. For example Muimo et al. suggested
that Annexin A1 may act in intracellular signaling. They found a new
phosphorylation site, at the histidine of the ANXA1 carboxyl-terminal
core. This phosphorylation was regulated by cAMP and AMP but not
cGMP. The hypothesized, but not characterized, kinase for phosphoryla-
tion of these residues was the nucleoside diphosphate kinase (NDK)
[28]. The residues proposed by the authors are the His246 and His293,
conserved in all the evaluated species.
6. TRPM7 channel-kinase (Chak1) and the Ser5 Annexin A1 residue
In 2004, a new kinase involved in ANXA1 phosphorylation has been
identiﬁed by Dorovkov & Ryazanov. They studied the TRPM7 channel-
kinase in mouse C2C12 cells. It is a bifunctional molecule consisting of
a TRP ion channel fused to a protein kinase domain. TRPM7was respon-
sible for phosphorylation of the serine 5 (Ser5) residue [29]. In 2009, the
study focused on an association between ANXA1 and TRPM7 conﬁrmed
the presence of a TRPM7/Annexin A1/Mg2+ complex, suggesting a
novel pathway in bradykinin signaling, dependent on PKC and c-src
[30]. Even though that pathway is not fully characterized, the same
team that discovered the Ser5 phosphorylation of ANXA1 also reported
crucial relevance of this modiﬁcation for ANXA1 membrane binding
and especially for the interaction between Annexin A1 and its known
partner, the calcium binding protein S100A11 [31]. This interaction is
biologically relevant, as the disruption of the Annexin A1/S100A1 com-
plex increased cervical cancer HeLa cells migration and clonogenic
growth via the EGF signaling alteration [32].
7. The subcellular phospho-Annexin A1 localization
A theory about the correlation between Annexin A1 phosphoryla-
tion and its intracellular localization emerged in 2000. The topic was
revitalized when Yoshii et al. found ANXA1 in rat liver mitochondria
and proved that the protein was phosphorylated on tyrosine residues
Table 1
Phosphorylation sites prediction by PredictProtein Server and relative involved kinases.
cAMP phosphor sites (PKA) Protein Kinase C (PKC) Casein Kinase 2 (CK2)
Thr 216 [2] Thr 24 [3] Thr 64
Ser 27[3] Thr 132
Thr 70 Thr 136
Thr 88 Thr 145
Thr 95 Thr 172
Thr 145 Ser 244
Thr 226 Ser 302
Thr 272 Thr 331
Phosphorylation sites prediction performed using PredictProtein Server [46] on whole
amino acid sequence of Annexin A1. In gray the already described and referenced
phosphorylation residues. The references are reported in [ ]. Thr and Ser are respectively
for Threonine and Serine.
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investigated.
Meanwhile, ANXA1 implication in growth regulation, differentiation
and apoptosis has been reported and further studies were performed.
Studies in human embryonic kidney HEK293 cells focused on Annexin
A1 cellular localization during PMA-induced mitogenic signal showed
cleavage of Annexin A1 which then migrated into the nucleus. The
PMA-induced nuclear translocation of ANXA1 was inhibited by the
PKCdelta-speciﬁc inhibitor, rottlerin, indicating that PKCdelta plays a
role in nuclear localization of cleaved ANXA1 [34]. Evenmore intriguing
is that dexamethasone induces changes in phosphorylation and subcel-
lular localization of Annexin A1, in A549 human adenocarcinoma cells.
The ANXA1 tyrosine phosphorylated co-localized with EGF-R, and its
amount was increased upon dexamethasone exposition. This effect
was reached in few minutes after dexamethasone stimulation and was
surprisingly completely reverted by RU486, a known glucocorticoid re-
ceptor inhibitor [35]. It has been suggested that the phosphorylated
Annexin A1 migrates to the cell membrane in order to interact with
EGF-R. This result paved the way to the following studies about the
Annexin A1 membrane localization. Nevertheless it was conﬁrmed
that Annexin A1 directly binds EGF-R during its internalization, but
the binding is not dependent on the phosphorylation of the ANXA1
N-terminus. In accord with these results, the binding between EGF-R
and Annexin A1 seems to be mediated through the Ca2+ binding core
domain [36].
8. The Ser27 phosphorylation and membrane localization
John et al. showed that PKC phosphorylates Annexin A1 and its activ-
ity is essential for both cellular export and biological activity of ANXA1 in
anterior pituitary glands. The ANXA1 exported from the cells contains
phospho-serines [37]. The phosphorylation of Annexin A1 on Ser27 is
crucial for migration to cell surface. This topic has been deepened by
Solito et al. in 2003 who published that dexamethasone induced signal-
ing caused translocation of a serine phosphorylated-ANXA1 to the cyto-
plasmic membrane of human folliculostellate cells (PDFS). These results
suggest that glucocorticoids induce rapid serine phosphorylation and
membrane translocation of ANXA1 via a novel glucocorticoid receptor-
dependent mechanism, which requires MAPK, phosphatidylinositiol
3-kinase and Ca2+-dependent PKC pathway [38]. Lately it has beenFig. 2. Principal cellular effects of ANXA1 phospshown that dexamethasone is also responsible for ANXA1 tyrosine
phosphorylation, but this modiﬁcation is not crucial for the Annexin
A1 membrane targeting [39]. It has been clearly shown that the
phosphorylation of Ser27 ANXA1 residue and its migration to the cell
membrane are implicated in hormones release. McArthur et al. pub-
lished recently the regulatory effects of ANXA1 on hormones exocytosis.
The authors focused on the release of adrenocorticotropin from a
corticotroph-like cell lines mediated by glucocorticoids. They conﬁrmed
an essential role of phosphorylation of ANXA1 serines 27 and 45 in its
translocation to the cell membrane and its inhibitory action on
hormones secretion. Moreover, the authors showed that the Annexin
A1-dependent inhibition of adrenocorticotrophin release involves an
enhancement of actin [40]. The complex ANXA1 role in the regulation
of endocrine function is reported in a review published in 2004 by
John et al. [41] (Fig. 2).
By that time, the physiological roles of Annexin A1 have been better
identiﬁed, which pointed to its important role in cell–cell communica-
tion in the host defense and neuroendocrine systems. In both systems
its actions are exerted extracellularly. The exposure to LPS caused phos-
phorylation of Ser27 ANXA1 and its translocation to the cell membrane.
The trafﬁcking of Ser27 phospho-ANXA1 to the cell surface was depen-
dent on activity of PI3-kinase andMAP-kinase. The serine phosphoryla-
tion was essential for the protein migration and an involvement of
isoprenyl lipids in this mechanism was identiﬁed. The isoprenyl lipidshorylation on the characterized residues.
Table 2
Phosphorylation residues and relative regulatory kinases.
Residue Ser5 [29] Tyr21 [1] Thr24 [3] Thr41[1] Ser27 [1] Ser28 [3] Ser45 [3] Thr216 [2] His246; His 293 [28]
Kinase TRPM7
channel
kinase
EGF-R
pp60c-src
IR
PKC PKC PKC PKC PKA NDK
Localization N-term. N-term. N-term. N-term. N-term. N-term. C-Term. core C-Term. core
Schematic representation of phosphorylation residues reported in the review and relative regulatory kinases. Ser, Tyr, Thr and His are respectively for serine, tyrosine, threonine and
histidine. N-term and C-term.core are abbreviations for the residue localization as N-terminal and C-terminal core. The kinases reported are TRPM7 (Chak1); Protein Kinase C (PKC);
Protein Kinase A (PKA); Nucleoside diphosphate kinase (NDK); Epidermal Growth Factor Receptor (EGF-R); Insulin Receptor (IR); Tyrosin Protein Kinase (pp60 c-src). References are
reported in [ ].
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ample transporters) or consensus sequences in ANXA1 [42].
9. Recent ﬁndings
In U937 cells, glucocorticoids treatment induced a rapid
concentration-dependent activation of PKCalpha/beta and a Ser27
Annexin A1 phosphorylation. Phosphorylated ANXA1was accumulated
on the cell membrane and externalized inhibited thromboxane forma-
tion. Simultaneous use of glucocorticoids with cromoglycate-like
drugs strongly increased Annexin A1 phosphorylation, migration and
effect on thromboxane. It could be due to the inhibition of the phospha-
tase PP2A effect exerted by cromoglycates. The authors suggested the
relevance of PP2A in a regulatory loop of Annexin A1 phosphorylation
important to limit the ANXA1 release [43].
Intriguingly, in 2008 Petrella et al. have shown that U937, K562 and
Jurkat leukemia cells exposed a Ser27 phosphorylated form of Annexin
A1 on the cell surface, during HDAC inhibitor induced apoptosis. The
phosphorylation and surface display appeared after 24 h of the treat-
ment, implicating a late mechanism of action. The authors discussed
the presence of Annexin A1 on the apoptotic cell surface both as an
“eat me” and as putative pro-apoptotic signal [44]. Interestingly the
phosphorylation of other residues has not yet been studied in the apo-
ptosis context.
In 2009, a new interesting implication for phosphorylated Annexin
A1 has been proposed by Côté et al. who showed that VEGF induces
ANXA1 phosphorylation via LIM kinase1 and p38 pathways. The phos-
phorylation activates Annexin A1and it is involved in endothelial cell
migration and tube formation [45]. Adopting a bioinformatics approach,
it is also possible to predict new putative phosphorylation sites targeted
by other kinases. For example the well-known PredictProtein Server
[46] identiﬁes residue substrates of the PKC and PKA, but not the phos-
phorylation depending by EFG-R. According to the server analysis some
residues could also be substrates for Casein Kinase 2 (CK2), kinase not
yet related to ANXA1 phosphorylation. The results obtained by
PredictProtein Server are summarized in Table 1.
Finally in 2013 Caron et al. showed the relevance of Y21 phosphory-
lation for the ANXA1 stability. In fact the authors demonstrated that the
tyrosine 21 phosphorylation is crucial for ANXA1 SUMOylation induced
by EGF [47] (Table 2).
10. Conclusions
A research conducted on human pituitary adenomas showed that in
all the patients the Annexin A1 was phosphorylated on the Ser27 resi-
due. Only few patients resulted positive to the ANXA1 tyrosine phos-
phorylation and in all the cases its expression was weak [48]. Recently
Annexin A1 has been described as a “double-face” protein, because of
its numerous, diverse and sometime opposing functions. Associated to
the well characterized FPR family receptors, it has been recently
shown that ANXA1 triggers also other receptor activity, binding several
partners. Its function may vary according to its cellular localization.
For this reason it is reasonable to consider the regulatory role
of post-transcriptional modiﬁcations of ANXA1, including selectivephosphorylation, as a key for the speciﬁc localizations, bindings and
functions of Annexin A1. In this respect ANXA1 could be regulated sim-
ilarly as numerous proteins and cytokines that change their mechanism
of action according to the phosphorylation, triggering structural switch.
It is intriguing that more than 20years of study of Annexin A1 phos-
phorylation have not provided detailed understanding of its role and
mechanism of action. It is no doubt that the phosphorylation is neces-
sary for ANXA1 regulation and activity. The hypothesis that phosphory-
lation of different ANXA1 residues couldwork as a switch-on/switch-off
mechanism is captivating. It could explain the number of Annexin A1
physiological functions and it could also bring the attention to speciﬁc
intracellular pathways and different receptor interactions. The complete
understanding of the phospho-ANXA1 physiological involvements and
the conformational changes due to the different phosphorylation tar-
gets could lead to newmodels and therapeutic approaches in treatment
of cancer, inﬂammation, diabetes and neurodegenerative diseases.
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